Subtopic Deep Dive

← Connective Tissue Growth Factor Research

CTGF in Fibrosis
Research Guide

What is CTGF in Fibrosis?

CTGF (Connective Tissue Growth Factor) drives fibrosis by promoting extracellular matrix deposition and myofibroblast activation in organs including lung, liver, kidney, and heart.

CTGF acts downstream of TGF-β to mediate fibrotic responses across multiple tissues (Lipson et al., 2012, 557 citations). Studies link elevated CTGF expression to disease progression in idiopathic pulmonary fibrosis and systemic sclerosis (Wynn, 2007, 1433 citations; Varga and Abraham, 2007, 1127 citations). Over 10 key papers from 1999-2020 detail its mechanisms and therapeutic targeting.

Curated Papers

Key Challenges

Why It Matters

CTGF inhibition reverses established fibrosis in preclinical models, offering intervention for chronic diseases like pulmonary fibrosis affecting 50,000 new US cases yearly (Lipson et al., 2012). In systemic sclerosis, CTGF correlates with multi-organ fibrosis progression, guiding anti-fibrotic therapies (Varga and Abraham, 2007). Wynn (2007) identifies CTGF-related pathways as shared across fibroproliferative diseases causing 45% of deaths worldwide. Frangogiannis (2020) highlights CTGF's role in TGF-β-driven cardiac and renal scarring, impacting millions with heart failure and kidney disease.

Key Research Challenges

CTGF-TGF-β Pathway Crosstalk

CTGF mediates TGF-β signaling but feedback loops complicate inhibition (Liu and Desai, 2015). Distinguishing CTGF-specific effects from TGF-β remains difficult (Frangogiannis, 2020). Walton et al. (2017) note SMAD pathway redundancy hinders selective targeting.

Organ-Specific Fibrosis Mechanisms

CTGF effects differ between lung, liver, and kidney fibrosis (Wynn, 2007). Varga and Abraham (2007) describe vasculopathy preceding fibrosis in systemic sclerosis. Translating lung findings to cardiac tissue lacks direct evidence (Lipson et al., 2012).

Clinical Translation of Inhibitors

Preclinical CTGF blockade reverses fibrosis but human trials show variable efficacy (Lipson et al., 2012). Ziesche et al. (1999) report mixed IFN-γ responses in pulmonary fibrosis. Biomarker validation for patient stratification is absent (Kasai et al., 2005).

Essential Papers

Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases

Thomas A. Wynn · 2007 · Journal of Clinical Investigation · 1.4K citations

Fibroproliferative diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, and macular degeneration, are a leading cause...

Transforming growth factor–β in tissue fibrosis

Nikolaos G. Frangogiannis · 2020 · The Journal of Experimental Medicine · 1.1K citations

TGF-β is extensively implicated in the pathogenesis of fibrosis. In fibrotic lesions, spatially restricted generation of bioactive TGF-β from latent stores requires the cooperation of proteases, in...

Systemic sclerosis: a prototypic multisystem fibrotic disorder

John Varga, David Abraham · 2007 · Journal of Clinical Investigation · 1.1K citations

A unique feature of systemic sclerosis (SSc) that distinguishes it from other fibrotic disorders is that autoimmunity and vasculopathy characteristically precede fibrosis. Moreover, fibrosis in SSc...

TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT)

Hidenori Kasai, Jeremy Allen, Roger M. Mason et al. · 2005 · Respiratory Research · 729 citations

Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis

Rui-Ming Liu, Leena P. Desai · 2015 · Redox Biology · 644 citations

Transforming growth factor beta (TGF-β) is the most potent pro-fibrogenic cytokine and its expression is increased in almost all of fibrotic diseases. Although signaling through Smad pathway is bel...

A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary Fibrosis

Rolf Ziesche, Elisabeth Hofbauer, Karin Wittmann et al. · 1999 · New England Journal of Medicine · 591 citations

In a preliminary study, 12 months of treatment with interferon gamma-1b plus prednisolone was associated with substantial improvements in the condition of patients with idiopathic pulmonary fibrosi...

CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis

Kenneth E. Lipson, Carol Wong, Yuchin Teng et al. · 2012 · Fibrogenesis & Tissue Repair · 557 citations

CTGF is a secreted matricellular protein with very complex biology. It has been shown to modulate many signaling pathways leading to cell adhesion and migration, angiogenesis, myofibroblast activat...

Reading Guide

Foundational Papers

Start with Wynn (2007, 1433 citations) for shared fibrosis mechanisms across organs, then Lipson et al. (2012, 557 citations) for CTGF's central role and reversibility evidence. Varga and Abraham (2007, 1127 citations) provides systemic sclerosis context.

Recent Advances

Frangogiannis (2020, 1135 citations) updates TGF-β/CTGF interactions. Liu and Desai (2015, 644 citations) covers ROS feedback. Walton et al. (2017, 546 citations) discusses SMAD targeting.

Core Methods

TGF-β1 EMT assays (Kasai et al., 2005). CTGF blockade in rodent models (Lipson et al., 2012). IFN-γ clinical trials (Ziesche et al., 1999). qPCR/ELISA for CTGF expression (Liu and Desai, 2015).

How PapersFlow Helps You Research CTGF in Fibrosis

Discover & Search

Research Agent uses citationGraph on Wynn (2007) to map 1400+ citing papers linking CTGF to multi-organ fibrosis, then findSimilarPapers reveals Lipson et al. (2012) for inhibition strategies. exaSearch queries 'CTGF fibrosis clinical trials' across 250M+ OpenAlex papers to uncover translational gaps beyond provided lists.

Analyze & Verify

Analysis Agent runs readPaperContent on Lipson et al. (2012) to extract CTGF inhibition data, then verifyResponse with CoVe cross-checks claims against Frangogiannis (2020). runPythonAnalysis with pandas quantifies CTGF expression correlations from Wynn (2007) datasets; GRADE grading scores evidence strength for myofibroblast activation pathways.

Synthesize & Write

Synthesis Agent detects gaps in CTGF cardiac fibrosis studies via contradiction flagging between Wynn (2007) and Varga (2007), generating exportMermaid diagrams of TGF-β/CTGF cascades. Writing Agent applies latexEditText to draft methods sections, latexSyncCitations for 10+ references, and latexCompile for publication-ready reviews.

Use Cases

"Extract and plot CTGF expression data from fibrosis papers to correlate with disease stage."

Research Agent → searchPapers('CTGF expression fibrosis datasets') → Analysis Agent → runPythonAnalysis(pandas plot from Lipson 2012 + Wynn 2007 tables) → matplotlib graph of expression vs. fibrosis score.

"Write LaTeX review on CTGF inhibition reversing lung fibrosis with citations."

Synthesis Agent → gap detection(Lipson 2012 + Ziesche 1999) → Writing Agent → latexEditText(draft section) → latexSyncCitations(10 papers) → latexCompile → PDF with TGF-β pathway figure.

"Find GitHub repos analyzing CTGF/TGF-β datasets from key fibrosis papers."

Research Agent → paperExtractUrls(Wynn 2007) → paperFindGithubRepo → Code Discovery → githubRepoInspect → verified analysis scripts for SMAD signaling simulations.

Automated Workflows

Deep Research workflow scans 50+ CTGF fibrosis papers starting with citationGraph on Lipson (2012), producing structured report with GRADE-scored interventions. DeepScan's 7-step chain verifies Wynn (2007) mechanisms via CoVe against Varga (2007), flagging organ-specific contradictions. Theorizer generates hypotheses on CTGF-ROS cycles from Liu and Desai (2015) + Frangogiannis (2020).

Try Doxa for CTGF in Fibrosis Research

Frequently Asked Questions

What defines CTGF's role in fibrosis?

CTGF promotes extracellular matrix deposition and myofibroblast differentiation downstream of TGF-β (Lipson et al., 2012). Elevated in lung, liver, kidney fibrosis (Wynn, 2007).

What are key methods studying CTGF in fibrosis?

In vitro EMT assays show TGF-β1 induces CTGF-driven transition (Kasai et al., 2005). In vivo models test CTGF antibodies reversing remodeling (Lipson et al., 2012). Clinical correlations use serum CTGF levels (Ziesche et al., 1999).

What are the most cited papers on CTGF fibrosis?

Wynn (2007, 1433 citations) covers mechanisms across fibrotic diseases. Lipson et al. (2012, 557 citations) proves CTGF inhibition reverses fibrosis. Varga and Abraham (2007, 1127 citations) details systemic sclerosis fibrosis.

What open problems exist in CTGF fibrosis research?

Selective CTGF inhibitors avoid TGF-β toxicity (Walton et al., 2017). Organ-specific biomarkers needed (Wynn, 2007). Long-term human trial data lacking post-Ziesche (1999).